Securities Registration: Employee Benefit Plan (s-8)
February 28 2019 - 4:10PM
Edgar (US Regulatory)
As filed with the Securities and Exchange Commission on February 28, 2019
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
S-8
REGISTRATION STATEMENT
UNDER
THE
SECURITIES ACT OF 1933
CYMABAY THERAPEUTICS, INC.
(Exact name of Registrant as specified in its charter)
|
|
|
Delaware
|
|
94-3103561
|
(State or other jurisdiction of incorporation or organization)
|
|
(I.R.S. Employer Identification No.)
|
7575 Gateway Blvd., Suite 110
Newark, California 94560
(Address of principal executive offices) (Zip code)
CymaBay
Therapeutics, Inc. 2013 Equity Incentive Plan
(Full title of the plan)
Sujal Shah
President
and Chief Executive Officer
CymaBay Therapeutics, Inc.
7575 Gateway Boulevard, Suite 110
Newark, California 94560
(510)
293-8800
(Name and address of agent for service) (Telephone number, including area code, of agent for service)
Copies to:
Matthew B. Hemington
Brett D. White
Cooley
LLP
3175 Hanover Street
Palo Alto, California 94304
(650)
843-5000
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
non-accelerated
filer, a smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company,
and emerging growth company in
Rule 12b-2
of the Exchange Act.
|
|
|
|
|
|
|
Large accelerated filer
|
|
☒
|
|
Accelerated filer
|
|
☐
|
|
|
|
|
Non-accelerated filer
|
|
☐
|
|
Smaller reporting company
|
|
☐
|
|
|
|
|
Emerging Growth Company
|
|
☐
|
|
|
|
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
CALCULATION
OF REGISTRATION FEE
|
|
|
|
|
|
|
|
|
|
Title of
Securities to be Registered
|
|
Amount
to be
Registered(1)(3)
|
|
Proposed
Maximum
Offering Price
Per Share(2)
|
|
Proposed
Maximum
Aggregate
Offering Price(2)
|
|
Amount of
Registration Fee
|
Common Stock, par value $0.0001 per share
|
|
2,378,259 shares
|
|
$10.02
|
|
$23,830,155.18
|
|
$2,888.21
|
|
|
(1)
|
Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the
Securities
Act
), this Registration Statement shall also cover any additional shares of Common Stock that become issuable under the Plan by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without
receipt of consideration that increases the number of the Registrants outstanding shares of Common Stock.
|
(2)
|
Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(h) and
Rule 457(c) promulgated under the Securities Act. The offering price per share and the aggregate offering price is based upon $10.02, which is the average of the high and low selling prices of the Registrants Common Stock as reported on the
Nasdaq Global Select Market on February 21, 2019.
|
(3)
|
Represents 2,378,259 shares of Common Stock added to the Companys 2013 Equity Incentive Plan.
|
EXPLANATORY NOTE
CymaBay Therapeutics, Inc. (the
Registrant
) is filing this Registration Statement on
Form S-8
for the purpose of registering an additional 2,378,259 shares of its Common Stock, issuable to eligible persons under the CymaBay Therapeutics, Inc. 2013 Equity Incentive Plan (
2013
Plan
), which Common Stock is in addition to the shares of Common Stock previously registered on the following Form
S-8s
(collectively, the
Prior Form
S-8s
):
|
|
|
the Registrants
Form S-8
filed on April 11, 2014 (File
No. 333-195211);
|
|
|
|
the Registrants Form
S-8
filed on August 21, 2014 (File
No. 333-198289);
|
|
|
|
the Registrants Form
S-8
filed on March 23, 2015 (File
No. 333-202941);
|
|
|
|
the Registrants Form
S-8
filed on March 29, 2016 (File
No. 333-210453);
|
|
|
|
the Registrants Form
S-8
filed on March 23, 2017 (File
No. 333-216905);
|
|
|
|
the Registrants Form
S-8
filed on March 15, 2018 (File
No. 333-223687);
and
|
|
|
|
the Registrants Form
S-8
filed on August 9, 2018 (File
No. 333-226741).
|
PART II
ITEM 3.
|
INCORPORATION BY REFERENCE
|
Pursuant to General Instruction E to Form
S-8,
the contents of the Prior Form
S-8s
are incorporated herein by reference and made a part hereof.
The following documents filed by the
Registrant with the Securities and Exchange Commission are incorporated by reference into this Registration Statement:
|
a)
|
The Registrants Annual Report on Form
10-K
filed on
February 28, 2019, under the Securities Exchange Act of 1934, as amended (the Exchange Act).
|
|
b)
|
The Registrants Current Report on Form
8-K
filed on
February 4, 2019 under the Exchange Act (File
No. 001-36500).
|
|
c)
|
The description of the Registrants common stock contained in the Registrants Form
8-A
filed on June 16, 2014, including any amendment or report filed for the purpose of updating such description.
|
|
d)
|
All documents, reports and definitive proxy or information statements filed by the Registrant pursuant to
Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form
8-K
and exhibits furnished on such form that relate to such items) on or after
the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered have been sold or that deregisters all securities then remaining unsold shall be
deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be
deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes
such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.
|
1
(1)
|
Previously filed as Exhibit 3.1 to the Registrants Amendment No. 2 to Registration Statement on Form
10/A (File
No. 000-55021),
filed with the Commission on October 17, 2013, and incorporated by reference herein.
|
(2)
|
Previously filed as Exhibit 3.2 to the Registrants Amendment No. 2 to Registration Statement on Form
10/A (File
No. 000-55021),
filed with the Commission on October 17, 2013, and incorporated by reference herein.
|
(3)
|
Previously filed as Exhibit 10.1 to the Registrants Current Report on Form
8-K
(File
No. 001-36500),
filed with the Commission on June 7, 2018, and incorporated by reference herein.
|
(4)
|
Previously filed as Exhibit 10.26 to the Registrants Amendment No. 2 to Registration Statement on
Form 10/A (File
No. 000-55021),
filed with the Commission on October 17, 2013, and incorporated by reference herein.
|
(5)
|
Previously filed as Exhibit 10.22 to the Registrants Form
10-K,
(File
No. 000-55021)
filed with the SEC on March 31, 2014.
|
2
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe
that it meets all of the requirements for filing on
Form S-8
and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Newark, State of
California, on this 28th day of February, 2019.
|
|
|
C
YMA
B
AY
T
HERAPEUTICS
, I
NC
.
|
|
|
By:
|
|
/s/ Sujal Shah
|
|
|
Sujal Shah
|
|
|
President and Chief Executive Officer
|
3
POWER OF ATTORNEY
K
NOW
A
LL
P
ERSONS
B
Y
T
HESE
P
RESENTS
, that each person whose signature appears below constitutes and appoints Sujal A. Shah, Daniel Menold and Paul Quinlan, and each of them, his or her true and lawful
attorney-in-fact
and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including
post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said
attorneys-in-fact
and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection
therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said
attorneys-in-fact
and agents, or
any of them, or their or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof.
Pursuant to the
requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.
|
|
|
|
|
Name and Signature
|
|
Title
|
|
Date
|
|
|
|
/s/ Sujal A. Shah
Sujal A. Shah
|
|
President, Chief Executive Officer and Director
(Principal Executive Officer)
|
|
February 28, 2019
|
|
|
|
/s/ Daniel Menold
Daniel Menold
|
|
Vice President, Finance
(Principal Financial and Accounting Officer)
|
|
February 28, 2019
|
|
|
|
/s/ Robert J. Wills
Robert J. Wills, Ph.D.
|
|
Director
|
|
February 28, 2019
|
|
|
|
/s/ Robert F. Booth
Robert F. Booth, Ph.D.
|
|
Director
|
|
February 28, 2019
|
|
|
|
/s/ Carl Goldfischer
Carl Goldfischer, M.D.
|
|
Director
|
|
February 28, 2019
|
|
|
|
/s/ Caroline Loewy
Caroline Loewy
|
|
Director
|
|
February 28, 2019
|
|
|
|
/s/ Evan A. Stein
Evan A. Stein, M.D., Ph D.
|
|
Director
|
|
February 28, 2019
|
|
|
|
/s/ Paul F. Truex
Paul F. Truex
|
|
Director
|
|
February 28, 2019
|
|
|
|
/s/ Kurt von Emster
Kurt von Emster, CFA
|
|
Director
|
|
February 28, 2019
|
|
|
|
/s/ Robert J. Weiland
Robert J. Weiland
|
|
Director
|
|
February 28, 2019
|
4
Cymabay Therapeutics (NASDAQ:CBAY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cymabay Therapeutics (NASDAQ:CBAY)
Historical Stock Chart
From Apr 2023 to Apr 2024